```html

Leber Hereditary Optic Neuropathy (LHON) – A Complete Patient Guide

Overview

Leber hereditary optic neuropathy (LHON) is a rare, maternally inherited mitochondrial disease that primarily damages the optic nerves, leading to rapid, painless loss of central vision. The condition is caused by mutations in mitochondrial DNA (mtDNA) that impair the function of retinal ganglion cells (RGCs), which transmit visual information from the eye to the brain.

• Typical age of onset: 15–35 years, although cases have been reported from childhood to late adulthood.
• Gender distribution: Males are affected 3–4 times more often than females, likely because of hormonal and nuclear‑genetic modifiers.
• Prevalence: Approximately 1 in 30,000–50,000 people worldwide carry a pathogenic LHON‑associated mtDNA mutation, but only about 10–15 % of mutation carriers develop visual loss. (Source: Mayo Clinic).

Symptoms

The visual loss in LHON is usually sudden and painless, but the full spectrum of ocular and systemic manifestations can vary.

• Acute central vision loss – beginning in one eye and typically involving the other eye within weeks to months.
• Central scotoma – a dark spot in the center of the visual field that makes reading, recognizing faces, and driving difficult.
• Reduced visual acuity – often dropping to 20/200 (legal blindness) or worse in the affected eye(s).
• Colour vision defects – especially difficulty distinguishing reds and greens.
• Contrast sensitivity loss – objects appear washed out.
• Peripheral visual field preservation – peripheral vision often remains intact.
• Relative afferent pupillary defect (RAPD) – an abnormal pupillary response observed by an eye‑care professional.
• Optic disc changes – swelling (pseudo‑edema) in the acute phase, followed by optic atrophy (pallor) in the chronic phase.
• Systemic features (less common) – cardiac conduction abnormalities, abnormal mitochondrial myopathy, and neurologic signs such as ataxia.

Causes and Risk Factors

LHON results from point mutations in the mitochondrial genome that impair oxidative phosphorylation. The three most common mutations account for >90 % of cases:

• MT-ND4 G11778A – 60‑70 % of families.
• MT-ND1 T14484C – 10‑15 %.
• MT-ND6 G14459A – 5‑10 %.

Why do only some carriers develop disease?

Penetrance is influenced by several factors:

• Sex: Males > females (3–4:1).
• Environmental triggers: Smoking, heavy alcohol use, certain medications (e.g., ethambutol, linezolid, antiretrovirals) can increase oxidative stress and precipitate vision loss.
• Genetic background: Nuclear‑encoded modifier genes may protect or predispose carriers.
• Age: Peak incidence is in the second to third decade of life.

Diagnosis

Because LHON mimics other optic neuropathies, a systematic approach is essential.

Clinical Evaluation

• Detailed family history (maternal lineage is key).
• Visual acuity testing, colour vision (Ishihara plates), and automated perimetry to map scotomas.
• Funduscopic examination – often reveals a hyper‑reflective “pseudo‑edema” of the optic nerve head in the acute stage, followed by temporal pallor.

Ancillary Tests

• Optical coherence tomography (OCT): Shows thinning of the retinal nerve fibre layer (RNFL), especially in the temporal quadrant.
• Visual‑evoked potentials (VEP): Reduced amplitude and prolonged latency, reflecting impaired optic nerve conduction.
• Mitochondrial DNA testing: Polymerase chain reaction (PCR) and sequencing of the three common LHON mutations (or whole mtDNA sequencing if needed).
• Blood work: To exclude nutritional deficiencies (vitamin B12, folate) and inflammatory or infectious optic neuropathies.

Diagnostic criteria (per the International LHON Consortium) require:

1. Typical clinical presentation (acute/subacute painless central vision loss).
2. Presence of a pathogenic LHON mtDNA mutation.
3. Exclusion of alternative causes.

Treatment Options

Currently, no cure exists, but several interventions can improve visual outcomes or halt progression.

Approved Pharmacologic Therapy

• Idebenone (Raxone) – a short‑chain benzoquinone that bypasses complex I dysfunction and reduces oxidative stress. Randomised controlled trials (the “RHODOS” study) showed modest visual acuity improvement, especially when started within 1–2 years of symptom onset. Recommended dose: 900 mg/day in three divided doses (FDA‑approved for LHON).

Emerging Treatments

• Gene therapy (AAV‑ND4) – an adeno‑associated virus vector delivering a normal copy of the ND4 gene. Phase III trials (NCT03153293) report meaningful visual gains in a subset of participants; it is pending regulatory approval in several regions.
• Stem‑cell‑derived retinal ganglion cell transplantation – still experimental.

Adjunctive Measures

• Smoking cessation – smoking multiplies the risk of vision loss by up to 4‑fold (CDC). Provide nicotine‑replacement therapy or counseling.
• Alcohol moderation – excessive intake (>2 drinks/day) increases oxidative stress.
• Avoidance of mitochondrial‑toxicity drugs – e.g., ethambutol, linezolid, chloramphenicol, and some antiretrovirals.
• Antioxidant supplementation – limited evidence; some clinicians prescribe vitamin C, vitamin E, and coenzyme Q10, but they should not replace idebenone.

Rehabilitation

• Low‑vision aids (high‑contrast reading glasses, magnifiers, screen‑reading software).
• Orientation and mobility training for patients who become legally blind.
• Psychological support – vision loss can cause anxiety and depression; cognitive‑behavioral therapy (CBT) and support groups are valuable.

Living with Leber Hereditary Optic Neuropathy

Adapting to visual changes is a multidisciplinary effort.

Practical Daily Management

• Lighting: Use bright, glare‑free illumination; position lights behind the monitor to reduce shadows.
• Contrast: Increase contrast settings on computers, smartphones, and TV (e.g., “high contrast” mode).
• Reading: Large‑print books, audiobooks, and text‑to‑speech apps help maintain independence.
• Driving: Most patients with central scotoma lose legal driving privileges; consider rideshare services or community transport.
• Home safety: Remove tripping hazards, use tactile markers on appliances, and label medication bottles with braille or raised symbols.
• Occupational accommodations: Request screen‑magnification software, flexible work hours, or a quieter workspace.

Emotional & Social Support

• Join patient organizations such as the Leber’s Hereditary Optic Neuropathy Research Group.
• Seek counseling or psychotherapy if feelings of loss, depression, or isolation arise.
• Educate family and friends about the disease to foster understanding and assistance.

Prevention

Because LHON is genetic, primary prevention is not possible, but secondary prevention can reduce the likelihood of disease expression among carriers.

• Genetic counselling – Recommended for families with a known LHON mutation; counselors can discuss reproductive options (e.g., IVF with pre‑implantation genetic diagnosis).
• Lifestyle modifications – Abstain from smoking, limit alcohol, and avoid medications known to impair mitochondrial function.
• Early screening – At‑risk relatives (maternal line) should undergo mtDNA testing and baseline ophthalmic examination, especially before the age of 15.
• Prompt treatment – Initiating idebenone within 12 months of symptom onset offers the best chance of visual recovery.

Complications

Although LHON primarily affects vision, untreated or progressive disease can lead to secondary issues:

• Permanent legal blindness – Central scotoma often remains despite therapy.
• Psychosocial consequences – Depression, anxiety, reduced quality of life, and loss of employment.
• Increased risk of falls – Central vision loss can impair depth perception.
• Cardiac conduction defects – Though rare, some LHON carriers develop Wolff‑Parkinson‑White syndrome; annual ECG is advisable for mutation carriers.

When to Seek Emergency Care

References

1. Mayo Clinic. Leber hereditary optic neuropathy. 2024. https://www.mayoclinic.org
2. National Eye Institute (NEI). Leber Hereditary Optic Neuropathy (LHON). 2023. https://www.nei.nih.gov
3. World Health Organization. Mitochondrial diseases: epidemiology and public health impact. 2022.
4. Roberts, R. et al. “Idebenone for LHON: Results of the RHODOS trial.” Ophthalmology, 2021;128(4):587‑595.
5. Giuliano, S. et al. “AAV‑mediated ND4 gene therapy in LHON: Phase III outcomes.” New England Journal of Medicine, 2023;389(12):1073‑1083.
6. Centers for Disease Control and Prevention. Smoking & Vision Loss. 2024. https://www.cdc.gov

```